(RS)-4-Carboxyphenylglycine

CAS No. 7292-81-1

(RS)-4-Carboxyphenylglycine( —— )

Catalog No. M33915 CAS No. 7292-81-1

(RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 52 Get Quote
5MG 75 Get Quote
10MG 112 Get Quote
25MG 183 Get Quote
50MG 274 Get Quote
100MG 390 Get Quote
500MG 821 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (RS)-4-Carboxyphenylglycine
  • Note
    Research use only, not for human use.
  • Brief Description
    (RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.
  • Description
    (RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    7292-81-1
  • Formula Weight
    195.17
  • Molecular Formula
    C9H9NO4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(O)=O)(N)C1=CC=C(C(O)=O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Bispyrazolone

    Bispyrazolone is white or light yellow crystalline powder.

  • Glenzocimab

    Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.

  • Lirilumab

    Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.